RENK BEFORE TAKEOVER? Will Evotec and AI gem NetraMark be swallowed up?

NetraMark Holdings: Strong performance = higher share prices or takeover

Donald Trump is shaking up the pharmaceutical industry in the US – and, with it, the world's largest market. Tariffs are intended to force pharmaceutical companies to invest in new production facilities in the US. Roche recently announced plans to invest USD 50 billion in the US. Other companies are likely to follow suit. This increases pressure on the industry to reduce costs and develop new drugs in order to recoup the costs of the plants. NetraMark should benefit from this. Researchers can use NetraMark's AI software to improve the design of clinical trials: the better the design, the lower the risk and costs – a billion-dollar market.

NetraMark has focused on the analysis of Phases 2 and 3, where failure rates are typically high. Most AI companies tend to avoid this segment, as AI and ML models generally prefer vast amounts of data, whereas clinical trials usually involve only a few hundred patients. However, with a novel topology-based algorithm from NetraMark, patient datasets can be broken down into subsets of strongly connected individuals based on multiple variables. This means that NetraMark can work with much smaller datasets to classify diseases into different types, categorize patients according to their sensitivity to drugs, and, of course, evaluate the effectiveness of treatments.

NetraMark AI is already being used successfully in practice. In a study on major depressive disorder (MDD), NetraAI-driven analysis of patient subpopulations achieved a 28% increase in model accuracy compared to traditional machine learning approaches. NetraAI delivered compelling results in the schizophrenia study. Patients with moderate to severe symptoms and mild behavioral disorders responded better to the drug olanzapine. In addition, there is a strategic partnership with Worldwide Clinical Trials (Worldwide). The contract research organization, with over 3,500 employees in more than 60 countries, conducts clinical trials for pharmaceutical and biotech companies. Worldwide will offer its customers the NetraAI platform to optimize their trials. This is expected to reduce the number of patients required per trial, shorten trial times, lower costs, and ultimately lead to higher success rates and more new drugs to cure diseases.

The share price performance in recent weeks confirms that NetraMark is on the right track operationally. The share price has remained stable despite the stock market turmoil. Given the potential savings for pharmaceutical and biotech companies, the valuation of less than CAD 150 million still appears favorable. The only question that remains is whether the share price will rise or whether a takeover will take place. Both should be interesting for investors.

Evotec: Millions from Bristol Myers Squibb

At Evotec, takeover speculation has cooled considerably. This is not entirely surprising, as, unlike NetraMark, the Company cannot focus on growth but must first implement a strategic realignment. Among other things, projects are to be sold as part of this realignment.

It is unknown whether the collaboration with Bristol Myers Squibb to develop a pipeline of molecular glues is under review, but there was a positive update yesterday. Evotec announced that performance- and program-related achievements have triggered payments totaling USD 75 million. Launched in 2018, the collaboration combines Evotec's powerful multi-omics screening and AI-driven data analytics and drug design capabilities with Bristol Myers Squibb's industry-leading library of cereblon E3 ligase modulators ("CELMoDs™). The partnership, expanded in 2022, continues to pursue the goal of identifying novel molecular glue degraders for highly relevant targets in oncology and beyond.

Evotec CSO Dr. Cord Dohrmann: "We are proud to see the continued expansion of our pipeline of molecular glue degraders together with Bristol Myers Squibb, a company that is a leader in this field. This highlights the value of our systematic and industrialized PanOmics-based approach. Our growing pipeline of molecular degraders, which addresses a broad range of highly relevant target structures, has enormous potential to bring multiple first-in-class products to market. We are well on track to achieve our goals."

The fact that this thoroughly positive news left the share price cold yesterday shows that Evotec is currently running out of steam.

RENK: Starting signal for a wave of takeovers?

Is the defense sector about to see a wave of major takeovers? In recent weeks and months, there have been several smaller acquisitions, for example, by Rheinmetall. Hensoldt CEO Oliver Dörre also hinted at a consolidation of the European defense industry in March. Hensoldt intends to play an active role in the wave of takeovers.

Could RENK be the first major defense company to be taken over? This is supported by the fact that it specializes in gearboxes and would, therefore, be a good fit for a manufacturer of tanks, for example. In addition, its market capitalization of EUR 5 billion is relatively modest. Rheinmetall is worth more than EUR 60 billion on the stock market, and Italy's Leonardo is worth around EUR 25 billion.

RENK could, for example, be swallowed up by KNDS. KNDS was formed from the merger of Germany's Krauss-Maffei Wegmann and France's Nexter and is known for producing the Leopard 2 battle tank. Incidentally, the Leopard 2's transmission is supplied by RENK. The German Federal Cartel Office recently approved KNDS's acquisition of a 25% + 1 share stake in RENK.

Andreas Mundt, President of the Federal Cartel Office, commented: "KNDS and RENK operate at different market levels. We examined in detail whether the acquisition could disadvantage other complete system suppliers who also purchase gearboxes and other components from RENK. However, based on the results of our investigation, this is not expected to be the case."

In February, KNDS agreed with financial investor Triton to purchase more than 18 million RENK shares. It is quite possible that this was just one step toward a complete takeover.

Conclusion

NetraMark is still an AI insider tip. Pharmaceutical and biotech companies engaged in research must cut costs while simultaneously developing new, lucrative drugs. NetraMark is likely to benefit from this. If operations continue to run smoothly, the stock will likely rise significantly or be taken over. The European defense industry is likely to face consolidation. However, due to government interests, mergers and acquisitions are likely to be anything but easy to implement. RENK is an attractive takeover candidate due to its niche position. At Evotec, investors currently seem to be waiting for a realignment or another drop in the share price.